Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2s)-3-(4-cyanophenoxy)-n-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
2. Gtx 024
3. Gtx-024
4. Mk 2866
5. Mk-2866
6. Mk2866
7. Ostarine
1. Ostarine
2. 841205-47-8
3. Gtx-024
4. Mk-2866
5. Enobosarm [usan]
6. Mk-2866 (gtx-024)
7. 1202044-20-9
8. Ostarine (mk2866)
9. Ostarine(mk-2866)
10. (2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
11. (s)-n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
12. Mk 2866
13. O3571h3r8n
14. Enobosarm (usan)
15. Propanamide, 3-(4-cyanophenoxy)-n-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-, (2s)-
16. Mk2866
17. ((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)
18. Enobosarm [usan:inn]
19. Gtx 024
20. Unii-o3571h3r8n
21. Ostarine-d4
22. (s)-ostarine
23. (2s)-3-(4-cyanophenoxy)-n-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
24. Enobosarm [inn]
25. Ostarine(mk-2286)
26. Enobosarm [who-dd]
27. Mls006010739
28. Sarm S-22
29. Schembl109069
30. Not For Sale-patented"
31. Chembl1738889
32. Dtxsid30233006
33. Ex-a638
34. Hms3654e16
35. Amy38131
36. Bcp02391
37. Bcp28483
38. Bdbm50529668
39. S1174
40. Zinc35793636
41. Akos005266718
42. Ccg-268514
43. Cs-0562
44. Db12078
45. Ex-8408
46. Sb16683
47. Ncgc00346499-01
48. Ac-30221
49. Hy-13273
50. Smr004701698
51. Sw219159-1
52. Ostarine(mk2286); 1202044-20-9
53. D10221
54. H12015
55. A864177
56. Q5379258
57. 1235370-13-4
58. Mk-2866(d4);mk2866(d4);gtx-024(d4);gtx024;(s)-n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide-d4
59. Mk-2866; Gtx024;((2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)
60. Propanamide, 3-?(4-?cyanophenoxy)?-?n-?[4-?cyano-?3-?(trifluoromethyl)?phenyl]?-?2-?hydroxy-?2-?methyl-?, (2s)?-
61. Rlj
| Molecular Weight | 389.3 g/mol |
|---|---|
| Molecular Formula | C19H14F3N3O3 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 389.09872580 g/mol |
| Monoisotopic Mass | 389.09872580 g/mol |
| Topological Polar Surface Area | 106 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 658 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Enobosarm manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Enobosarm, including repackagers and relabelers. The FDA regulates Enobosarm manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Enobosarm API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Enobosarm supplier is an individual or a company that provides Enobosarm active pharmaceutical ingredient (API) or Enobosarm finished formulations upon request. The Enobosarm suppliers may include Enobosarm API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Enobosarm as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Enobosarm API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Enobosarm as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Enobosarm and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Enobosarm NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Enobosarm suppliers with NDC on PharmaCompass.
Enobosarm Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Enobosarm GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Enobosarm GMP manufacturer or Enobosarm GMP API supplier for your needs.
A Enobosarm CoA (Certificate of Analysis) is a formal document that attests to Enobosarm's compliance with Enobosarm specifications and serves as a tool for batch-level quality control.
Enobosarm CoA mostly includes findings from lab analyses of a specific batch. For each Enobosarm CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Enobosarm may be tested according to a variety of international standards, such as European Pharmacopoeia (Enobosarm EP), Enobosarm JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Enobosarm USP).
LOOKING FOR A SUPPLIER?
